2019冠状病毒病中血栓形成风险增加：证据与争议
Increased Thrombotic Risk in COVID-19: Evidence and Controversy.
作者信息
De Vita Antonio, Franceschi Francesco, Covino Marcello
机构信息
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
出版信息
J Clin Med. 2023 Jul 1;12(13):4441. doi: 10.3390/jcm12134441.
Abstract
The pandemic of respiratory disease caused by the novel coronavirus named SARS-CoV-2, which emerged at the end of 2019, is still ongoing [...].
摘要
由新型冠状病毒SARS-CoV-2引起的呼吸道疾病大流行于2019年底出现，目前仍在持续[……]
相似文献
1
Increased Thrombotic Risk in COVID-19: Evidence and Controversy.2019冠状病毒病中血栓形成风险增加：证据与争议
J Clin Med. 2023 Jul 1;12(13):4441. doi: 10.3390/jcm12134441.
2
The Coronavirus Pandemic: What Does the Evidence Show?新冠疫情：证据表明了什么？
J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9. doi: 10.33314/jnhrc.v18i1.2596.
3
The diagnostic methods in the COVID-19 pandemic, today and in the future.新冠疫情时期及未来的诊断方法。
Expert Rev Mol Diagn. 2020 Sep;20(9):985-993. doi: 10.1080/14737159.2020.1816171. Epub 2020 Sep 16.
4
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防：回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
5
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
6
Review of Thoracic Imaging Manifestations of COVID-19 and Other Pathologic Coronaviruses.COVID-19 及其他病理性冠状病毒的胸部影像学表现综述。
Radiol Clin North Am. 2022 May;60(3):359-369. doi: 10.1016/j.rcl.2022.01.004. Epub 2022 Jan 11.
7
COVID-19: a conundrum to decipher.COVID-19：一个待破译的谜。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.
8
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.新型严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）的爆发：当前全球状况综述。
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.
9
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情：一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
10
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
引用本文的文献
1
Thromboembolic Events in the Era of COVID-19: A Detailed Narrative Review.COVID-19 时代的血栓栓塞事件：详细叙述性综述
Can J Infect Dis Med Microbiol. 2025 Mar 4;2025:3804576. doi: 10.1155/cjid/3804576. eCollection 2025.
2
Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables.评估 COVID-19 风险因素与临床和实验室变量预测模型的早期和长期死亡率。
BMC Infect Dis. 2024 Jul 9;24(1):685. doi: 10.1186/s12879-024-09592-7.
本文引用的文献
1
Editorial COVID-19 and Thrombosis 2023: New Waves of SARS-CoV-2 Infection, Triage Organization in Emergency Department and the Association of VOCs/VOI with Pulmonary Embolism.社论：2023年新型冠状病毒肺炎与血栓形成——严重急性呼吸综合征冠状病毒2感染的新一波疫情、急诊科的分诊组织以及变异型关切病毒/变异型感兴趣病毒与肺栓塞的关联
Viruses. 2022 Nov 5;14(11):2453. doi: 10.3390/v14112453.
2
The Role of Heparin in COVID-19: An Update after Two Years of Pandemics.肝素在新冠疫情中的作用：大流行两年后的最新情况
J Clin Med. 2022 May 30;11(11):3099. doi: 10.3390/jcm11113099.
3
The Use of Oral Anticoagulation Is Not Associated With a Reduced Risk of Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies.口服抗凝药的使用与新冠病毒病患者死亡率降低无关：队列研究的系统评价和荟萃分析
Front Pharmacol. 2022 Mar 31;13:781192. doi: 10.3389/fphar.2022.781192. eCollection 2022.
4
High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.COVID-19住院患者高剂量与标准剂量血栓预防的比较：一项系统评价和荟萃分析
J Clin Med. 2021 Nov 26;10(23):5549. doi: 10.3390/jcm10235549.
5
Incidence and Predictors of Thrombotic Complications in 4742 Patients with COVID-19 or Other Acute Infectious Respiratory Diseases: A Propensity Score-Matched Study.4742例新冠肺炎或其他急性感染性呼吸道疾病患者血栓形成并发症的发生率及预测因素：一项倾向评分匹配研究
J Clin Med. 2021 Oct 26;10(21):4973. doi: 10.3390/jcm10214973.
6
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
7
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
8
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
9
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.标准预防剂量与中等剂量依诺肝素在重症 COVID-19 成人患者中的应用：一项多中心、开放标签、随机对照试验。
J Thromb Haemost. 2021 Sep;19(9):2225-2234. doi: 10.1111/jth.15450. Epub 2021 Jul 18.
10
Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症的辅助免疫球蛋白。
N Engl J Med. 2021 Aug 19;385(8):720-728. doi: 10.1056/NEJMoa2107051. Epub 2021 Jun 9.
Zotero 插件